The latest price target for CASI Pharmaceuticals (NASDAQ:CASI) was reported by HC Wainwright & Co. on May 19, 2025. The analyst firm set a price target for $4.00 expecting CASI to rise to within 12 months (a possible 220.00% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for CASI Pharmaceuticals (NASDAQ:CASI) was provided by HC Wainwright & Co., and CASI Pharmaceuticals reiterated their buy rating.

There is no last upgrade for CASI Pharmaceuticals

There is no last downgrade for CASI Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CASI Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CASI Pharmaceuticals was filed on May 19, 2025 so you should expect the next rating to be made available sometime around May 19, 2026.

While ratings are subjective and will change, the latest CASI Pharmaceuticals (CASI) rating was a reiterated with a price target of $4.00 to $4.00. The current price CASI Pharmaceuticals (CASI) is trading at is $1.25, which is out of the analyst’s predicted range.